Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Stefan, Tiefenbacher"'
Autor:
Katherine A. High, Mary Robinson, Marcus E. Carr, Stefan Tiefenbacher, Benjamin J. Samelson-Jones, Valder R. Arruda, John E. Murphy, Denis Rybin, Lindsey A. George, Jeremy Rupon
Publikováno v:
Journal of Thrombosis and Haemostasis
Background Limited information exists regarding the factor IX (FIX) coagulant activity (FIX:C) measured by different assays following FIX‐Padua gene therapy. Objective Assess for the first time FIX:C in five commonly used coagulation assays in plas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595917b7168693d6570fdf4c8b369d6c
https://doi.org/10.1111/jth.15281
https://doi.org/10.1111/jth.15281
Autor:
Emily Symington, Glenn F. Pierce, Adam Giermasz, K. John Pasi, Stefan Tiefenbacher, Stephen J. Zoog, Mary Robinson, Savita Rangarajan, Steffen Rosen, Christian Vettermann, Donnie Mackenzie, Jaydeep K. Srimani, Benjamin Kim, Mei Huang, Terri Christianson
Publikováno v:
Blood. 136:2524-2534
Adeno-associated virus (AAV)-based gene therapies can restore endogenous factor VIII (FVIII) expression in hemophilia A (HA). AAV vectors typically use a B-domain–deleted FVIII transgene, such as human FVIII-SQ in valoctocogene roxaparvovec (AAV5-F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7b54fc4a67379b3e101a905a194db2a
https://doi.org/10.1182/blood.2020005683
https://doi.org/10.1182/blood.2020005683
Publikováno v:
Haemophilia
Aim N8‐GP (turoctocog alfa pegol) is a glycoPEGylated, extended half‐life human recombinant factor VIII (FVIII) shown to be an efficacious treatment for patients with haemophilia A. Accurate monitoring of replacement therapy helps ensure proper d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9b695a6f4909e7df9a2895347cb984
http://europepmc.org/articles/PMC6852407
http://europepmc.org/articles/PMC6852407
Autor:
Vimal K. Derebail, Jing Zhu, Matthew L. Crawford, Julia R. Garnier, Karlyn A. Martin, Sarah Skinner, Tejendra Patel, Anne Froment, Margaret R. Sketch, Andy H. Szeto, Sheel M. Patel, Chad D. Torrice, Stefan Tiefenbacher, Dorothy M. Adcock, Russell P. Grant, Nigel S. Key, Daniel J. Crona
Publikováno v:
American journal of kidney diseases : the official journal of the National Kidney Foundation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c33e5bda08b7e7504aa6241ff02bde89
https://pubmed.ncbi.nlm.nih.gov/36328100
https://pubmed.ncbi.nlm.nih.gov/36328100
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 27
The treatment options for the haemostatic disorders, haemophilia A and haemophilia B, have progressed rapidly over the last decade. The introduction of extended half-life recombinant factor VIII (FVIII) and factor IX (FIX) concentrates to replace the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edb9aee2616fe97d32d27321d458f0b
https://pubmed.ncbi.nlm.nih.gov/32469128
https://pubmed.ncbi.nlm.nih.gov/32469128
Publikováno v:
Seminars in Thrombosis and Hemostasis. 43:331-337
The advent of modified factor VIII (FVIII) and factor IX (FIX) molecules with extended half-lives (EHLs) compared with native FVIII and FIX represents a major advance in the field of hemophilia care, with the potential to reduce the frequency of prop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40620b1adf4565e32f66d285c9db772c
https://doi.org/10.1055/s-0037-1598058
https://doi.org/10.1055/s-0037-1598058
Autor:
Johanna A. Kremer Hovinga, Tiago Vicente, Guenther Kappert, Stefan Tiefenbacher, Manuela Albisetti, Peter Baker, Carin Borgvall, Catherine Ternisien, Olaf Walter, Larisa Belyanskaya, Ute Scholz, Claire Pouplard, Johannes Oldenburg, Steve Kitchen
Publikováno v:
Tiefenbacher, Stefan; Albisetti, Manuela; Baker, Peter; Kappert, Guenther; Kitchen, Steve; Kremer Hovinga, Johanna A.; Pouplard, Claire; Scholz, Ute; Ternisien, Catherine; Borgvall, Carin; Vicente, Tiago; Belyanskaya, Larisa; Walter, Olaf; Oldenburg, Johannes (2019). Estimation of Nuwiq® (simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study. Haemophilia, 25(4), pp. 708-717. Wiley 10.1111/hae.13763
Haemophilia
Haemophilia
BACKGROUND Accurate determination of coagulation factor VIII activity (FVIII:C) is essential for effective and safe FVIII replacement therapy. FVIII C can be measured by one-stage and chromogenic substrate assays (OSAs and CSAs, respectively); howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9ce45bc0bcad9fef20b2011538e3503
https://www.zora.uzh.ch/id/eprint/179542/
https://www.zora.uzh.ch/id/eprint/179542/
Autor:
Roxy Gode, Tyler Allison, Amanda Pikas, Mary Robinson, Caroline Cogswell, Erin McEwan, Emily Burger, Jennifer Littlefield, Brian F Poirier, Andrea Schmoker, Stefan Tiefenbacher
Publikováno v:
Blood. 136:20-20
Background:Emicizumab, a humanized bispecific antibody, has been approved for the prophylactic treatment of hemophilia A in patients with and without inhibitors. Both activated partial thromboplastin time (APTT) based FVIII:C and inhibitor assays, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6220d54a5f8bf148a22dca67df71bb2
https://doi.org/10.1182/blood-2020-142132
https://doi.org/10.1182/blood-2020-142132
Publikováno v:
MLO: medical laboratory observer. 49(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e2de71e7381ead60441e7ae6dd3bb2d5
https://pubmed.ncbi.nlm.nih.gov/30005473
https://pubmed.ncbi.nlm.nih.gov/30005473
Autor:
Johannes C.M. Van der Loo, Jerome M. Teitel, Benjamin J. Samelson-Jones, Adam Cuker, Xavier M. Anguela, Marcus E. Carr, Catherine E. McGuinn, Yifeng Chen, Linda B. Couto, Adam Giermasz, Suvankar Majumdar, Katie Wachtel, Jonathan M. Ducore, Stefan Tiefenbacher, Margaret V. Ragni, J. Fraser Wright, Olga Zelenaia, Katherine A. High, Yun Liu, John E.J. Rasko, Daniel Takefman, Lisa M. Sullivan, Angela Winters, Daniel Hui, Alvin Luk, Spencer K. Sullivan, Valder R. Arruda, Lindsey A. George
Publikováno v:
The New England journal of medicine. 377(23)
The prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in the treatment of hemophilia.We infused a si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbb2657407ff2d3c3546fcc638e6677
https://pubmed.ncbi.nlm.nih.gov/29274719
https://pubmed.ncbi.nlm.nih.gov/29274719